Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1978 1
1980 1
1981 2
1982 1
1983 2
1985 1
1986 1
1989 1
1990 2
1991 2
1993 2
1994 2
1995 6
1996 5
1997 9
1998 7
1999 7
2000 11
2001 11
2002 18
2003 13
2004 8
2005 26
2006 30
2007 22
2008 24
2009 30
2010 36
2011 41
2012 51
2013 81
2014 110
2015 118
2016 126
2017 117
2018 136
2019 166
2020 179
2021 237
2022 288
2023 279
2024 286
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,256 results

Results by year

Filters applied: . Clear all
Page 1
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Horwitz S, O'Connor OA, Pro B, Trümper L, Iyer S, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Illidge T. Horwitz S, et al. Among authors: miao h. Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16. Ann Oncol. 2022. PMID: 34921960 Free PMC article. Clinical Trial.
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy AH, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Bot AA, Shen RR, Dong J, Singh K, Miao H, Kim JJ, Zheng Y, Locke FL. Neelapu SS, et al. Among authors: miao h. Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893. Blood. 2023. PMID: 36821768 Free PMC article.
Drug conjugate-based anticancer therapy - Current status and perspectives.
Yang Y, Wang S, Ma P, Jiang Y, Cheng K, Yu Y, Jiang N, Miao H, Tang Q, Liu F, Zha Y, Li N. Yang Y, et al. Among authors: miao h. Cancer Lett. 2023 Jan 1;552:215969. doi: 10.1016/j.canlet.2022.215969. Epub 2022 Oct 22. Cancer Lett. 2023. PMID: 36279982 Free article. Review.
Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.
Zhang Y, Zuo C, Liu L, Hu Y, Yang B, Qiu S, Li Y, Cao D, Ju Z, Ge J, Wang Q, Wang T, Bai L, Yang Y, Li G, Shao Z, Gao Y, Li Y, Bian R, Miao H, Li L, Li X, Jiang C, Yan S, Wang Z, Wang Z, Cui X, Huang W, Xiang D, Wang C, Li Q, Wu X, Gong W, Liu Y, Shao R, Liu F, Li M, Chen L, Liu Y. Zhang Y, et al. Among authors: miao h. J Hepatol. 2021 Nov;75(5):1128-1141. doi: 10.1016/j.jhep.2021.06.023. Epub 2021 Jun 23. J Hepatol. 2021. PMID: 34171432 Free article.
Metabolomics in dyslipidemia.
Chen H, Miao H, Feng YL, Zhao YY, Lin RC. Chen H, et al. Among authors: miao h. Adv Clin Chem. 2014;66:101-19. doi: 10.1016/b978-0-12-801401-1.00004-9. Adv Clin Chem. 2014. PMID: 25344987 Review.
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trümper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Savage KJ, et al. Among authors: miao h. Blood Adv. 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971. Blood Adv. 2022. PMID: 35470385 Free PMC article. Clinical Trial.
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.
Zhang P, Narayanan E, Liu Q, Tsybovsky Y, Boswell K, Ding S, Hu Z, Follmann D, Lin Y, Miao H, Schmeisser H, Rogers D, Falcone S, Elbashir SM, Presnyak V, Bahl K, Prabhakaran M, Chen X, Sarfo EK, Ambrozak DR, Gautam R, Martin MA, Swerczek J, Herbert R, Weiss D, Misamore J, Ciaramella G, Himansu S, Stewart-Jones G, McDermott A, Koup RA, Mascola JR, Finzi A, Carfi A, Fauci AS, Lusso P. Zhang P, et al. Among authors: miao h. Nat Med. 2021 Dec;27(12):2234-2245. doi: 10.1038/s41591-021-01574-5. Epub 2021 Dec 9. Nat Med. 2021. PMID: 34887575
2,256 results